RVNC vs. PEPG, NKTX, HRTX, MRSN, ANRO, NATR, ORGO, BMEA, ESPR, and CRBP
Should you be buying Revance Therapeutics stock or one of its competitors? The main competitors of Revance Therapeutics include PepGen (PEPG), Nkarta (NKTX), Heron Therapeutics (HRTX), Mersana Therapeutics (MRSN), Alto Neuroscience (ANRO), Nature's Sunshine Products (NATR), Organogenesis (ORGO), Biomea Fusion (BMEA), Esperion Therapeutics (ESPR), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical preparations" industry.
Revance Therapeutics (NASDAQ:RVNC) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment.
Revance Therapeutics presently has a consensus target price of $13.75, indicating a potential upside of 304.41%. PepGen has a consensus target price of $24.67, indicating a potential upside of 106.76%. Given Revance Therapeutics' higher probable upside, equities analysts clearly believe Revance Therapeutics is more favorable than PepGen.
PepGen has lower revenue, but higher earnings than Revance Therapeutics. PepGen is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.
97.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by insiders. Comparatively, 4.0% of PepGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, PepGen had 1 more articles in the media than Revance Therapeutics. MarketBeat recorded 3 mentions for PepGen and 2 mentions for Revance Therapeutics. PepGen's average media sentiment score of 0.77 beat Revance Therapeutics' score of 0.67 indicating that PepGen is being referred to more favorably in the news media.
Revance Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, PepGen has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
PepGen has a net margin of 0.00% compared to Revance Therapeutics' net margin of -138.43%. Revance Therapeutics' return on equity of 0.00% beat PepGen's return on equity.
Revance Therapeutics received 383 more outperform votes than PepGen when rated by MarketBeat users. However, 85.71% of users gave PepGen an outperform vote while only 63.92% of users gave Revance Therapeutics an outperform vote.
Summary
PepGen beats Revance Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Revance Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVNC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revance Therapeutics Competitors List
Related Companies and Tools
